<SEC-DOCUMENT>0000950170-24-048364.txt : 20240425
<SEC-HEADER>0000950170-24-048364.hdr.sgml : 20240425
<ACCEPTANCE-DATETIME>20240425162511
ACCESSION NUMBER:		0000950170-24-048364
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240425
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240425
DATE AS OF CHANGE:		20240425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		24876751

	BUSINESS ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		7209402200

	MAIL ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abio-20240425.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-04-25T14:04:43.5988+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:abio="http://www.arcabiopharma.com/20240425">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_bc55526c-9653-4ae5-ba99-2e24ec254d80" name="dei:EntityCentralIndexKey" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7">0000907654</ix:nonNumeric><ix:nonNumeric id="F_8824899a-43ef-4f67-abcf-12ac3716e181" name="dei:AmendmentFlag" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="abio-20240425.xsd"/></ix:references><ix:resources><xbrli:context id="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-25</xbrli:startDate><xbrli:endDate>2024-04-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3cc40c7-8412-43e5-8a0a-acc127283de2" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_ca9ba0c7-7ad9-4f92-ba19-6dafd210a33a" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">April 25, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57f6eb0f-ca2f-4780-bfc1-30d153c3b11c" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">ARCA biopharma, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:18%;"/>
    <td style="width:41%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b13291ee-1620-4c41-aa76-b17e6f290773" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_204b636e-e452-4d85-949d-43b30c1bf239" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">000-22873</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_49480fc5-0af7-4c03-adce-9496163fcdeb" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">36-3855489</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_47bf2c59-73c9-4125-aa5a-ad1cd1991e65" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10170 Church Ranch Way</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_741a4fbd-906e-42c3-8dc1-a31c8799a355" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 100</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5dda8a97-db5f-4a5b-abea-f3f3f54980c2" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Westminster</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_53ae1381-e6b8-4586-8e81-01872732d78d" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Colorado</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_491831d2-e86e-4d96-bcf9-2e0a18115fdb" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">80021</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_b4e14bf9-2e3c-4d7b-b756-6a5a9d923a6c" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(720)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_f07122c3-2051-4c82-8a71-69a107e50436" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">940-2200</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2deba3f5-96a4-4c4f-818e-f795df6a9a75" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f206382f-208d-4b8c-a32b-93ab48c7a268" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e73bdab-b742-4d6a-a234-c4ae25811517" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0177deb1-b02f-4267-a54c-3a83b39c79d8" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_02f27f01-c0bb-44d4-9550-b1e6ec175d4a" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_80774928-8f7f-45ff-96eb-cb672ea07470" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ABIO</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0f78e5c9-5a0c-43d1-b063-2f20bfe91628" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_c50cffb4-c901-4fcd-bba6-4c464ec733e2" contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 2 &#8212; Financial Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 25, 2024, ARCA biopharma, Inc., or ARCA, issued a press release reporting financial results for the quarter ended March 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The press release is attached hereto as Exhibit 99.1, which is furnished under Item 2.02 of this report and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No Offer or Solicitation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Current Report on Form 8-K and the exhibits filed or furnished herewith are not intended to and do not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM 8-K AND THE EXHIBITS FILED OR FURNISHED HEREWITH ARE TRUTHFUL OR COMPLETE.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Important Additional Information About the Proposed Transaction Will be Filed with the SEC</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Current Report on Form 8-K and the exhibits filed or furnished herewith are not substitutes for the registration statement or for any other document that ARCA may file with the SEC in connection with the proposed transaction. In connection with the proposed transaction between ARCA and Oruka, ARCA intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement/prospectus of ARCA. ARCA URGES INVESTORS AND STOCKHOLDERS TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ARCA, ORUKA, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and stockholders will be able to obtain free copies of the proxy statement/prospectus and other documents filed by ARCA with the SEC (when they become available) through the website maintained by the SEC at</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> www.sec.gov</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In addition, investors and stockholders should note that ARCA communicates with investors and the public using its website (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">www.arcabio.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and the investor relations website (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">www.arcabio.com/investors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) where anyone will be able to obtain free copies of the proxy statement/prospectus and other documents filed by ARCA with the SEC and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Participants in the Solicitation</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARCA, Oruka and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the proposed transaction. Information about ARCA&#8217;s directors and executive officers including a description of their interests in ARCA is included in ARCA&#8217;s most recent Annual Report on Form 10-K, as filed with the SEC on February 1, 2024. Additional information regarding these persons and their interests in the proposed transaction will be included in the proxy statement/prospectus relating to the proposed transaction when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 9 &#8212; Financial Statements and Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.14%;"/>
    <td style="width:10.06%;"/>
    <td style="width:78.8%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit Number</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="abio-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release titled &#8220;ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update&#8221; dated April 25, 2024</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101).</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;"/>
    <td style="width:44%;"/>
    <td style="width:4%;"/>
    <td style="width:46%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ARCA biopharma, Inc.<br/></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Registrant)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">April 25, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ C. Jeffrey Dekker</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: C. Jeffrey Dekker <br/>Title: Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>abio-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><img src="img123434494_0.jpg" alt="img123434494_0.jpg" style="width:203px;height:69px;">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">------------------------------------------------------------------------------------------------------------</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ARCA biopharma and Oruka Therapeutics announce Merger Agreement</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ARCA biopharma appoints Thomas Keuer as President</font></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="ole_link5"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Westminster, CO, April 25, 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> &#x2013;</font><font id="ole_link6"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARCA biopharma, Inc.</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (Nasdaq: ABIO), (the &#x201c;Company&#x201d;) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In April 2022, ARCA established a Special Committee of the board of directors (the &#x201c;Board&#x201d;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. The Company has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">On April 3, 2024, following a comprehensive review of strategic alternatives, the Company, Atlas Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of ARCA (&#x201c;Merger Sub I&#x201d;), Atlas Merger Sub II LLC, a Delaware limited liability company and a wholly-owned subsidiary of ARCA (&#x201c;Merger Sub II&#x201d;) and Oruka Therapeutics, Inc., a Delaware corporation (&#x201c;Oruka&#x201d;), entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#x201c;First Merger&#x201d;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub II with Merger Sub II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#x201c;Second Merger&#x201d; and together with the First Merger, the &#x201c;Merger&#x201d;). The Merger is intended to qualify for federal income tax purposes as a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional descriptions about the Merger Agreement and related agreements were</font><font style="color:#202529;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> previously </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">disclosed on a Current Report on Form 8-K filed with the SEC on April 3, 2024.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that the Company does not complete the Merger, the Company may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of the Company.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective April 3, 2024, ARCA and Dr. Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr. Bristow&#x2019;s employment and service as a director.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In connection with Dr. Bristow&#x2019;s separation, ARCA and Dr. Bristow entered into a separation agreement (the &#x201c;Separation Agreement&#x201d;) on April 3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr. Bristow a lump sum payment equal to (i) twelve (12) months of Dr. Bristow&#x2019;s base salary as of the last date of his employment and (ii) a cash payment of $25,000, less applicable withholdings. The severance benefits were conditioned on the non-revocation by Dr. Bristow of a legal release of claims.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARCA and Dr. Bristow entered into a consulting agreement, effective April 3, 2024 (the &#x201c;Consulting Agreement&#x201d;), pursuant to which Dr. Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i) the completion of services under the Consulting Agreement, (ii) a termination in accordance with the terms of the Consulting Agreement, and (iii) upon a Change of Control (as defined in ARCA&#x2019;s 2020 Equity Incentive Plan (the &#x201c;Plan&#x201d;)). Pursuant to the Consulting Agreement, Dr. Bristow's provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#202529;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Appointment of Thomas Keuer as President</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#202529;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#202529;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective as of April 3, 2024, the Board appointed Thomas A. Keuer, the Company&#x2019;s Chief Operating Officer, to serve as ARCA&#x2019;s President and principal executive officer. Mr. Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine years, a position he will continue to serve in. Mr. Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr. Keuer&#x2019;s position will end upon closing of the Merger as previously disclosed on a Current Report on Form 8-K filed with the SEC on April 3, 2024.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">First Quarter 2024 Summary Financial Results</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">were $35.9 million as of March 31, 2024, compared to $37.4 million as of December 31, 2023. ARCA believes that its current cash and cash equivalents, consisting primarily of money market funds, will be sufficient to fund its operations through the middle of 2025. Our future viability beyond that point is dependent on the results of the strategic review process and our ability to raise additional capital to fund our operations. We expect to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that we will be able to successfully consummate any particular strategic transaction, including the Merger. The process of continuing to evaluate these strategic options may be very costly, time-consuming and complex and we have incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General and administrative (G&amp;A) expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> were $2.3 million for the quarter ended March 31, 2024, compared to $1.4 million for the corresponding period in 2023, an increase of approximately $0.9 million. During the quarter ended March 31, 2023, ARCA recorded $159,000 for one-time termination benefits related to the mutually agreed to conclusion of Christopher D. Ozeroff's employment, the former Secretary, Senior Vice President and General Counsel of ARCA, effective March 31, 2023. The increase for the three month period was primarily a result of a $1.1 million increase in professional fees primarily related to the Merger Agreement discussed above, offset by $0.2 million lower one-time termination benefits and lower personnel costs from the reduction discussed above in 2023. G&amp;A expenses in 2024 are expected to be higher than those in 2023 as we incur professional fees related to the Merger Agreement discussed above and maintain administrative activities to support our ongoing operations. We expect to incur significant costs related to our exploration of strategic alternatives and the Merger, including legal, accounting and advisory expenses and other related charges.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Research and development (R&amp;D) expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> were $0.2 million for the quarter ended March 31, 2024, compared to $0.4 million for the corresponding period in 2023. The $0.2 million decrease in R&amp;D expenses in 2024 as compared to 2023 was primarily related to decreased headcount and a $0.1 million decrease related to the unrestricted research grants with ARCA&#x2019;s former President and Chief Executive Officer&#x2019;s academic research laboratory at the University of Colorado. There was no expense under these arrangements for the three months ended March 31, 2024. Total expense under these arrangements for the three months ended March 31, 2023 was $0.1 million. In December 2023, the Company made a payment of $125,000 for the grant period July 2022 through December 2023 under these arrangements. As discussed above, the former President and Chief Executive Officer resigned in April 2024. R&amp;D expense in 2024 is expected to be lower than 2023 while we explore strategic alternatives. Should we resume clinical trials of product candidates, we expect research and development costs to increase significantly for the foreseeable future as our product candidate development programs progress.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Total operating expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> for the quarter ended March 31, 2024 were $2.5 million compared to $1.8 million for the first quarter 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Net loss</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> for the quarter ended March 31, 2024 was $2.0 million, or $0.14 per basic and diluted share, compared to $1.3 million, or $0.09 per basic and diluted share in the first quarter of 2023.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About ARCA biopharma</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARCA biopharma is dedicated to developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">www.arcabio.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> or follow the Company on LinkedIn.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Safe Harbor Statement</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">This press release contains &#34;forward-looking statements&#34; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995 concerning ARCA, Oruka, the proposed pre-closing financing and the proposed merger between ARCA and Oruka (collectively, the &#x201c;Proposed Transactions&#x201d;) and other matters. These statements include, but are not limited to, express or implied statements relating to ARCA&#x2019;s or Oruka&#x2019;s management team&#x2019;s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the Proposed Transactions and the expected effects, perceived benefits or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">opportunities, including investment amounts from investors and expected proceeds, and related timing with respect thereto, expectations regarding or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to ORKA-001 and ORKA-002, and any developments or results in connection therewith, including the target product profile of each of ORKA-001 and ORKA-002; the anticipated timing of the commencement of and results from those studies and trials; expectations regarding the use of proceeds, the sufficiency of post-transaction resources to support the advancement of Oruka&#x2019;s pipeline through certain milestones and the time period over which Oruka&#x2019;s post-transaction capital resources will be sufficient to fund its anticipated operations; the cash balance of the combined entity at closing; expectations regarding the treatment of psoriasis and associated diseases; expectations related to ARCA&#x2019;s contribution and payment of dividends in connection with the Merger, including the timing thereof; the expected trading of the combined company&#x2019;s stock on Nasdaq under the ticker symbol &#x201c;ORKA;&#x201d; potential future development plans for Gencaro, including ARCA&#x2019;s ability to continue development of Gencaro; ARCA&#x2019;s ability to secure sufficient financing to support any clinical trials for Gencaro: and the ability of ARCA&#x2019;s financial resources to support its operations at the current levels through the middle of fiscal year 2025, ARCA&#x2019;s ability to obtain additional funding when needed or enter into a strategic or other transaction, the extent to which our issued and pending patents may protect our products and technology, the potential of such product candidates to lead to the development of safe or effective therapies, our ability to enter into collaborations, or our ability to maintain listing of our common stock on a national exchange. These and other factors are identified and described in more detail in ARCA&#x2019;s filings with the Securities and Exchange Commission, including without limitation ARCA&#x2019;s annual report on Form 10-K for the year ended December 31, 2023, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, ARCA undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Offer or Solicitation</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This press release and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the Proposed Transactions or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS PRESS RELEASE IS TRUTHFUL OR COMPLETE.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Important Additional Information About the Proposed Transactions Will be Filed with the SEC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This press release is not a substitute for the registration statement or for any other document that ARCA may file with the SEC in connection with the Proposed Transactions. In connection with the Proposed Transactions between ARCA and Oruka, ARCA intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement/prospectus of ARCA. ARCA URGES INVESTORS AND STOCKHOLDERS TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ARCA, ORUKA, THE PROPOSED TRANSACTIONS AND RELATED MATTERS. Investors and stockholders will be able to obtain free copies of the proxy statement/prospectus and other documents filed by ARCA with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the Proposed Transactions. In addition, investors and stockholders should note that ARCA communicates with investors and the public using its website (https://arcabio.com/investors/).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participants in the Solicitation</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARCA, Oruka and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the Proposed Transactions. Information about ARCA&#x2019;s directors and executive officers including a description of their interests in ARCA is included in ARCA&#x2019;s most recent Annual Report on Form 10&#x2011;K, including any information incorporated therein by reference, as filed with the SEC. Additional information regarding these persons and their interests in the transaction will be included in the proxy statement/prospectus relating to the Proposed Transactions when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Investor &amp; Media Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Jeff Dekker</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">720.940.2122</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ir@arcabio.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(Tables follow)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">###</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARCA BIOPHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BALANCE SHEET DATA</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">						   </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:52.12%;"></td>
    <td style="width:24.329%;"></td>
    <td style="width:23.551%;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">March 31, 2024</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">December 31, 2023</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$35,903</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$37,431</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Working capital</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$35,089</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$36,955</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$36,706</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$37,861</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$35,125</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$37,020</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARCA BIOPHARMA, INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STATEMENTS OF OPERATIONS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.602%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:15.151%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:2.019%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:15.151%;"></td>
    <td style="width:1.019%;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="6" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="6" style="vertical-align:top;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands, except share<br>and per share amounts)</font></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Costs and expenses:</font></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,317</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,406</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">390</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total costs and expenses</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,482</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,796</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,482</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,796</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest and other income</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">473</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">450</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</font></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,009</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,346</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-top:2.25pt double #ffffff03;vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share:</font></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic and diluted</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.14</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.09</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average shares outstanding:</font></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic and diluted</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,501,143</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,410,143</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img123434494_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img123434494_0.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #8 GH# 2(  A$! Q$!_\0
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MS2TBOQ._\5?M :UJCO%H\:Z3:]!(0'F8?4\+^'YUYWJ/B#5-88M?:E=79/\
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M"EOAY>+;P/JTOO+=Q)_+-',@Y6?9=%?$$G_!3"+8=G@"7?VW:F /_1=3VO\
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M\(^&]3US49/*L=.MY+J9_144D_RK\:_'GC*]^(7C36O$NHG_ $S5+I[EE_N
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M5IQET8I1ZH^L****T,PHHJKJFJV>AZ;=:AJ%S'9V-K&TT]Q,VU(T49+$^@%
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M> ?C)X7NKV![6[TO6X!<02C:R,LH5U;]17[(GK1'8)[A1115D!1110 4444
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M\9?]<H?_ $<E?E17ZK_MI?\ )M/C+_KE#_Z.2ORHK*6YK'8[WX ?\ER\!?\
M89MO_0Z_8BOQW^ '_)<O 7_89MO_ $.OV(JH$R"BBBK("OSX_P""DVEI;_$;
MPAJ"@;[K2Y8F]?W<N1_Z,-?H/7Y[_P#!2;5%N/B1X2L 1NM=*DE([_O)<?\
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MUC)69M%W1^IO[%OQ,/Q&^!NE17$WFZGH9.EW.XY8A /*8_5"OX@U[Q7YL_\
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MK+5NZ-=$K,^L_P#AH;X8_P#0^:#_ .!R?XT?\-#_  R_Z'S0?_ Y/\:^8?\
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M^+N%.OKEOSK4_P"&%/C-_P!"]8_^#6#_ .*K]2**7*A\S/RSF_8:^,L$9?\
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M[XD^!?[1'Q0O$E\2:-KVJR*<I_:EY&(T/J%W[5_ 5^HM%)QN-2L?EK'^PO\
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M?4?^_P O_P 37J%%>9_J_E7_ $#Q^XZ/KV*_Y^,\P_X9W\,?\]]1_P"_R_\
MQ-'_  SSX8_Y[ZC_ -_E_P#B:]/HH_U?RK_H'C]P?7L5_P _&>8_\,\^&?\
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M>N* LSM:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR&Q#$WH2/O'V'YUFIJWQ8DT677'73;:WC0S_ -GR18E* 9/';CL3FN9_9_\
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M6ZQ\?/&*W[ 16^E@<BV>V)(';);FO7?!7Q1M=:\ OXAUAH]/%M(T-P5/REP
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV^-   N.A./>O:J*35]QIM;%72]-@T?3;6QM4V6]O&L2*/0#%6J**8@HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$=Q,MM!),^=D:EVP,G &3Q7BWCGX\-<:5/::#I=]'+,I0WEU"8Q&#P2J]SZ9
MHHK.<FMC2$4]SQ7P_>QZ'XBTR]O+=YH+>X2:2$C!=0<GK7UKX/\ '^C>.HYW
MTF:21H-OFQR1,A3.<9SP>AZ&BBI@];%S6ESHJ***V, HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>abio-20240425.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-04-25T14:04:43.9986+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.arcabiopharma.com/20240425" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:abio="http://www.arcabiopharma.com/20240425" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="abio-20240425.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139871401818304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 25,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCA biopharma, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-22873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-3855489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10170 Church Ranch Way<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Westminster<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(720)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">940-2200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABIO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MYQ3WWD,^R/U;&+-LS4].LEN$'H/Y7?![$Y-[M-:U_QM\9W9FJDG"5Z#D70U
M6.V6XKL=(_-R^;N4!A;3Y6;,&923O0#.KZ0TAQV[HJ[^$)G\!U!+ P04
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M2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @ )8.96"0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ )8.96 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  E@YE8&P-+/.\    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    ( "6#F5@ZJJ+G0 $  #P"   /
M  "  640  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  E@YE8)!Z;HJT
M  #X 0  &@              @ '2$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  E@YE899!YDAD!  #/ P  $P
M@ &W$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   !%
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="abio-20240425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="abio-20240425.htm">abio-20240425.htm</File>
    <File>abio-20240425.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "abio-20240425.htm": {
   "nsprefix": "abio",
   "nsuri": "http://www.arcabiopharma.com/20240425",
   "dts": {
    "inline": {
     "local": [
      "abio-20240425.htm"
     ]
    },
    "schema": {
     "local": [
      "abio-20240425.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_21d90fa8-2bb7-4e44-adb7-16b943a025a7",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abio-20240425.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_21d90fa8-2bb7-4e44-adb7-16b943a025a7",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abio-20240425.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.arcabiopharma.com/20240425/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-048364-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-048364-xbrl.zip
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MRHK7V'<Q(3B:+$_%[30,T[> '6:[F)'+DDD.NGM44/,!8B6#1R #05#%>:J
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MW!8EO;6LMDL'>/X<5O\;K&^PW@6K4=$?M-HHZ__ $-BJW>+B ,<-7P^W/[\
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M)C?A2B0E/@F3\U/<%, D/>MU4XV$QVFG!$R"5 /AQ%('^I(HQZK7K!6/8Y$
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MJ4HPC4B.T:;08>10U3=B#5'R"->6S&:S&FQN#ARLP?9\_!M+\' K'<0OF('
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MSW]_]WJ23+V?_Q]02P$"% ,4    "  E@YE8:#_$B%09  "RO   $0
M        @ $     86)I;RTR,#(T,#0R-2YH=&U02P$"% ,4    "  E@YE8
M,G'%188(   U80  $0              @ &#&0  86)I;RTR,#(T,#0R-2YX
M<V102P$"% ,4    "  E@YE8O<2X(Y\@  #_) $ #P              @ $X
H(@  86)I;RUE>#DY7S$N:'1M4$L%!@     #  , NP    1#      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>abio-20240425_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abio-20240425.xsd" xlink:type="simple"/>
    <context id="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-04-25</startDate>
            <endDate>2024-04-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_bc55526c-9653-4ae5-ba99-2e24ec254d80">0000907654</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_8824899a-43ef-4f67-abcf-12ac3716e181">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_b3cc40c7-8412-43e5-8a0a-acc127283de2">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_ca9ba0c7-7ad9-4f92-ba19-6dafd210a33a">2024-04-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_57f6eb0f-ca2f-4780-bfc1-30d153c3b11c">ARCA biopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_b13291ee-1620-4c41-aa76-b17e6f290773">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_204b636e-e452-4d85-949d-43b30c1bf239">000-22873</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_49480fc5-0af7-4c03-adce-9496163fcdeb">36-3855489</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_47bf2c59-73c9-4125-aa5a-ad1cd1991e65">10170 Church Ranch Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_741a4fbd-906e-42c3-8dc1-a31c8799a355">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_5dda8a97-db5f-4a5b-abea-f3f3f54980c2">Westminster</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_53ae1381-e6b8-4586-8e81-01872732d78d">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_491831d2-e86e-4d96-bcf9-2e0a18115fdb">80021</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_b4e14bf9-2e3c-4d7b-b756-6a5a9d923a6c">(720)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_f07122c3-2051-4c82-8a71-69a107e50436">940-2200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_2deba3f5-96a4-4c4f-818e-f795df6a9a75">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_f206382f-208d-4b8c-a32b-93ab48c7a268">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_4e73bdab-b742-4d6a-a234-c4ae25811517">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_0177deb1-b02f-4267-a54c-3a83b39c79d8">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_02f27f01-c0bb-44d4-9550-b1e6ec175d4a">Common</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_80774928-8f7f-45ff-96eb-cb672ea07470">ABIO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_0f78e5c9-5a0c-43d1-b063-2f20bfe91628">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_21d90fa8-2bb7-4e44-adb7-16b943a025a7"
      id="F_c50cffb4-c901-4fcd-bba6-4c464ec733e2">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
